THE WOODLANDS, Texas,
Oct. 26 /PRNewswire-FirstCall/ --
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical
company focused on discovering breakthrough treatments for human
disease, announced today that it will release its third quarter
2010 financial results on Friday, November
5, 2010 before the financial markets open. Lexicon
management will hold a conference call to discuss its clinical
development progress and financial results for the quarter at
11:00 a.m. Eastern Time that same
day.
The dial-in number for the conference call is 888-220-1244
(within the US/Canada) or
706-679-5615 (international). The conference ID for all
callers is 20791091. Investors can access a live webcast of
the call at www.lexpharma.com. An archived version of the
webcast will be available on the website through November 12, 2010.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
breakthrough treatments for human disease. Lexicon currently
has four drug candidates in mid-stage development for diabetes,
irritable bowel syndrome, carcinoid syndrome and rheumatoid
arthritis, all of which were discovered by Lexicon's research team.
Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has
focused drug discovery efforts on these biologically-validated
targets to create its extensive pipeline of clinical and
preclinical programs. For additional information about
Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's growth and
future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other
matters that are not historical facts or information. All
forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors that may cause Lexicon's actual results to
be materially different from any future results expressed or
implied by such forward-looking statements. Information
identifying such important factors is contained under "Factors
Affecting Forward-Looking Statements" and "Risk Factors" in
Lexicon's annual report on Form 10-K for the year ended
December 31, 2009, as filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright . 26 PR Newswire